Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
BMJ Supportive & Palliative Care|December 31, 2024
Postcancer rehabilitation: multidisciplinary exercise - programme organisation and feasibilityChloé Drozd, Quentin Jacquinot, Sophie Paget-Bailly, et al.
BMJ Oncology|January 31, 2025
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trialLaurie Spehner, Emeline Orillard, Antoine Falcoz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohortXavier Pivot, Pierre Fumoleau, Jean-Yves Pierga, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2025
Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF TrialSéverine Guiu, Judith Balmaña, Pablo Lemercier, et al.
Cancer Research|May 20, 2016
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell ImmunityLaurent Beziaud, Laura Mansi, Patrice Ravel, et al.
Bulletin Du Cancer|October 4, 2016
[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté]Fanny Dénommé, Marie Kroemer, Philippe Montcuquet, et al.
European Journal of Cancer (Oxford, England : 1990)|July 2, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)Volkmar Mueller, Andrew Wardley, Elisavet Paplomata, et al.
Oncotarget|October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patientsDavid G Cox, Elsa Curtit, Gilles Romieu, et al.
Breast Cancer Research : BCR|August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomesElsa Curtit, Xavier Pivot, Julie Henriques, et al.
Pageof 5